The stock has a 36-month beta value of 1.41. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DNA is 1.35B, and at present, short sellers hold a 20.08% of that float. On April 22, 2024, the average trading volume of DNA was 23.06M shares.
DNA) stock’s latest price update
The stock price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) has plunged by -6.46 when compared to previous closing price of 0.92, but the company has seen a -14.37% decline in its stock price over the last five trading sessions. The Motley Fool reported 2024-04-09 that These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
DNA’s Market Performance
Ginkgo Bioworks Holdings Inc (DNA) has experienced a -14.37% fall in stock performance for the past week, with a -24.79% drop in the past month, and a -28.52% drop in the past quarter. The volatility ratio for the week is 10.28%, and the volatility levels for the past 30 days are at 7.79% for DNA. The simple moving average for the last 20 days is -18.21% for DNA stock, with a simple moving average of -44.92% for the last 200 days.
Analysts’ Opinion of DNA
Many brokerage firms have already submitted their reports for DNA stocks, with Raymond James repeating the rating for DNA by listing it as a “Mkt Perform.” The predicted price for DNA in the upcoming period, according to Raymond James is $2.50 based on the research report published on November 14, 2023 of the previous year 2023.
Goldman gave a rating of “Sell” to DNA, setting the target price at $1.25 in the report published on June 02nd of the previous year.
DNA Trading at -28.06% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.02% of loss for the given period.
Volatility was left at 7.79%, however, over the last 30 days, the volatility rate increased by 10.28%, as shares sank -24.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.25% lower at present.
During the last 5 trading sessions, DNA fell by -14.37%, which changed the moving average for the period of 200-days by -53.25% in comparison to the 20-day moving average, which settled at $1.0437. In addition, Ginkgo Bioworks Holdings Inc saw -48.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Dmytruk Mark E., who sale 51,169 shares at the price of $1.05 back on Apr 02 ’24. After this action, Dmytruk Mark E. now owns 865,079 shares of Ginkgo Bioworks Holdings Inc, valued at $53,727 using the latest closing price.
Dmytruk Mark E., the of Ginkgo Bioworks Holdings Inc, sale 38,826 shares at $1.26 during a trade that took place back on Mar 04 ’24, which means that Dmytruk Mark E. is holding 808,125 shares at $48,765 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -3.34 for the present operating margin
- 0.75 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -3.55. The total capital return value is set at -0.56. Equity return is now at value -63.02, with -42.47 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.18. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 150.16.
Currently, EBITDA for the company is -600.68 million with net debt to EBITDA at 1.33. When we switch over and look at the enterprise to sales, we see a ratio of 4.59. The receivables turnover for the company is 7.92for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.11.
Conclusion
To sum up, Ginkgo Bioworks Holdings Inc (DNA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
